PRJNA505127
C. difficile infection inhibited by B. fragilis on mice
Clostridium difficile is currently the leading cause of nosocomial infection. Antibiotics remain the first-line therapy for C. difficile-associated diseases (CDAD), despite the risks of resistance promotion and further gut microbiota perturbation. Notably, the abundance of Bacteroides fragilis was reported to be significantly decreased in CDAD patients. This study aimed to clarify the prophylactic effects of B. fragilis strain ZY-312 in a mouse model of C. difficile infection (CDI).The bacterial diversity and relative abundance of gut microbiota were significantly improved on CDI mouse. Interestingly, the relative abundance of Akkermansia muciniphila was positively correlated with B. fragilis treatment.